Brokers Offer Predictions for LRMR Q2 Earnings

Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Equities research analysts at Wedbush issued their Q2 2026 earnings estimates for Larimar Therapeutics in a report issued on Wednesday, April 30th. Wedbush analyst L. Chico anticipates that the company will earn ($0.41) per share for the quarter. The consensus estimate for Larimar Therapeutics' current full-year earnings is ($1.15) per share. Wedbush also issued estimates for Larimar Therapeutics' Q3 2026 earnings at ($0.45) EPS, Q4 2026 earnings at ($0.48) EPS, FY2028 earnings at $0.75 EPS and FY2029 earnings at $4.83 EPS.

LRMR has been the topic of a number of other research reports. Truist Financial began coverage on shares of Larimar Therapeutics in a research report on Wednesday, January 29th. They issued a "buy" rating and a $18.00 price objective on the stock. Guggenheim reiterated a "buy" rating and issued a $26.00 price objective on shares of Larimar Therapeutics in a research report on Tuesday, March 25th. Citigroup reissued a "buy" rating on shares of Larimar Therapeutics in a report on Tuesday, March 25th. HC Wainwright boosted their price objective on Larimar Therapeutics from $15.00 to $16.00 and gave the stock a "buy" rating in a research note on Tuesday, March 25th. Finally, Robert W. Baird cut their price objective on Larimar Therapeutics from $13.00 to $10.00 and set an "outperform" rating for the company in a research report on Tuesday, March 25th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $19.63.

Larimar Therapeutics Trading Up 4.5 %

Shares of LRMR traded up $0.10 during trading hours on Friday, reaching $2.20. 951,250 shares of the company traded hands, compared to its average volume of 739,359. The stock's fifty day moving average price is $2.34 and its 200 day moving average price is $4.15. Larimar Therapeutics has a 12-month low of $1.61 and a 12-month high of $11.20. The firm has a market cap of $140.54 million, a price-to-earnings ratio of -1.90 and a beta of 0.93.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.04).

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Jane Street Group LLC lifted its position in Larimar Therapeutics by 80.1% in the 3rd quarter. Jane Street Group LLC now owns 113,783 shares of the company's stock valued at $745,000 after acquiring an additional 50,622 shares in the last quarter. Barclays PLC boosted its holdings in Larimar Therapeutics by 321.2% during the third quarter. Barclays PLC now owns 60,032 shares of the company's stock worth $393,000 after purchasing an additional 45,781 shares during the last quarter. Virtu Financial LLC acquired a new stake in Larimar Therapeutics in the 3rd quarter valued at $71,000. Franklin Resources Inc. boosted its stake in shares of Larimar Therapeutics by 21.9% during the 3rd quarter. Franklin Resources Inc. now owns 19,723 shares of the company's stock worth $143,000 after buying an additional 3,549 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of Larimar Therapeutics by 18.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 21,771 shares of the company's stock valued at $143,000 after acquiring an additional 3,425 shares in the last quarter. Institutional investors and hedge funds own 91.92% of the company's stock.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.